A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.
Also called NCT03499704
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 133 participants
- Sponsor
- Celltrion Pharm, Inc.
- Registry
-
NCT03499704
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03499704. Randomized; no masking; primary purpose treatment. Start 2020-02-11 (actual); primary completion 2024-01-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
- Acronym
- EPIDOTE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Pioglitazone + Alogliptin
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Celltrion Pharm, Inc.
Record details
- Record id
cardio:ct-nct03499704- Content hash
74fd786735c14713897292a20e769f0f7f1d51d6ee7400655ad1404c724a6c00